Hikma Names Injectables Chief Mishlawi As CEO
New Chief Replaces Interim Leader Darwazah Following Olafsson’s Departure Last Year
Executive Summary
Hikma’s president of injectables, Riad Mishlawi, has been chosen to become the firm’s new CEO from the start of September. The move comes after a period of success in injectables for Hikma, at the same time as the firm attempts to revive the fortunes of its generics business.
You may also be interested in...
What’s Next? Five Things To Look Out For In September
Generics Bulletin previews the most notable and anticipated events for September 2023.
Hikma Marks Milestone With US Injectables Launches
Hikma has passed a milestone with its US injectables portfolio after the latest trio of launches.
Wave Of New Leaders Could Reshape Generics Industry
With a number of top generics and biosimilars firms announcing new leaders over the past few months, the industry could be in for some strategic shifts as new faces take the helm at established off-patent players.